Grant opportunity · PAR-25-374
Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Who can apply (as listed)
- Public and state-controlled institutions of higher education
- Small businesses
- County governments
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- Independent school districts
- Special district governments
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- Public housing authorities / Indian housing authorities
- State governments
- Others (see the opportunity text)
- City or township governments
- Native American tribal governments (federally recognized)
- Native American tribal organizations (other than federally recognized governments)
- Private institutions of higher education
- For-profit organizations (other than small businesses)
This Notice of Funding Opportunity (NOFO) invites applications that propose to use mouse models to conduct rigorous preclinical testing of drugs or drug combinations currently used for other conditions, as well as investigational drugs at various stages of clinical development, predicted to be efficacious in AD/ADRD. This initiative will also support preclinical testing of repurposable or investigational drug candidates in combination with non-pharmacologic interventions leading to robust translational outcomes. The central goal is to establish robust proof of concept that will enable rational drug repurposing and combination therapy development for the treatment and prevention of AD/ADRD.
Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.
GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.